CN110885281B - 一类四环二萜类化合物及其制备方法与应用 - Google Patents
一类四环二萜类化合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN110885281B CN110885281B CN201911072144.7A CN201911072144A CN110885281B CN 110885281 B CN110885281 B CN 110885281B CN 201911072144 A CN201911072144 A CN 201911072144A CN 110885281 B CN110885281 B CN 110885281B
- Authority
- CN
- China
- Prior art keywords
- vena
- vend
- venezuelan
- venc
- venezuelae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 125000002389 tetracyclic diterpenoid group Chemical group 0.000 title claims abstract 5
- 238000002360 preparation method Methods 0.000 title claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 46
- 241000588724 Escherichia coli Species 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 22
- 239000000126 substance Substances 0.000 claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 108091008053 gene clusters Proteins 0.000 claims abstract description 17
- 230000014509 gene expression Effects 0.000 claims abstract description 11
- 230000008569 process Effects 0.000 claims abstract description 9
- 239000003205 fragrance Substances 0.000 claims abstract description 8
- 230000004913 activation Effects 0.000 claims abstract description 5
- 241000531819 Streptomyces venezuelae Species 0.000 claims description 39
- 229930002348 tetracyclic diterpenoid Natural products 0.000 claims description 29
- -1 tetracyclic diterpenoid compound Chemical class 0.000 claims description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 241000894006 Bacteria Species 0.000 claims description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- 238000012258 culturing Methods 0.000 claims description 15
- 239000013604 expression vector Substances 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 14
- 238000003752 polymerase chain reaction Methods 0.000 claims description 14
- 239000001963 growth medium Substances 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 230000001851 biosynthetic effect Effects 0.000 claims description 11
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims description 8
- 101710118490 Copalyl diphosphate synthase Proteins 0.000 claims description 7
- 101710174833 Tuberculosinyl adenosine transferase Proteins 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 229930004069 diterpene Natural products 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims description 6
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 claims description 6
- 108010066605 Geranylgeranyl-Diphosphate Geranylgeranyltransferase Proteins 0.000 claims description 6
- 238000012408 PCR amplification Methods 0.000 claims description 6
- 230000036983 biotransformation Effects 0.000 claims description 6
- 230000004186 co-expression Effects 0.000 claims description 6
- 150000004141 diterpene derivatives Chemical class 0.000 claims description 6
- 238000000855 fermentation Methods 0.000 claims description 6
- 230000004151 fermentation Effects 0.000 claims description 6
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 claims description 6
- 229960000210 nalidixic acid Drugs 0.000 claims description 6
- 102100039291 Geranylgeranyl pyrophosphate synthase Human genes 0.000 claims description 5
- 101100316898 Vibrio vulnificus (strain CMCP6) venB gene Proteins 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 229960000723 ampicillin Drugs 0.000 claims description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 229960005091 chloramphenicol Drugs 0.000 claims description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- 229930027917 kanamycin Natural products 0.000 claims description 4
- 229960000318 kanamycin Drugs 0.000 claims description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 4
- 229930182823 kanamycin A Natural products 0.000 claims description 4
- 239000003643 water by type Substances 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 241001655322 Streptomycetales Species 0.000 claims description 3
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 claims description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 3
- CBIDRCWHNCKSTO-UHFFFAOYSA-N prenyl diphosphate Chemical compound CC(C)=CCO[P@](O)(=O)OP(O)(O)=O CBIDRCWHNCKSTO-UHFFFAOYSA-N 0.000 claims description 3
- 239000008223 sterile water Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 2
- 235000011180 diphosphates Nutrition 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 4
- 241000187747 Streptomyces Species 0.000 abstract description 2
- 150000003505 terpenes Chemical class 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 229940041514 candida albicans extract Drugs 0.000 description 9
- 239000012138 yeast extract Substances 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- XVULBTBTFGYVRC-HHUCQEJWSA-N sclareol Chemical compound CC1(C)CCC[C@]2(C)[C@@H](CC[C@](O)(C)C=C)[C@](C)(O)CC[C@H]21 XVULBTBTFGYVRC-HHUCQEJWSA-N 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 239000012137 tryptone Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 5
- 229930014626 natural product Natural products 0.000 description 5
- 239000002304 perfume Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- XVULBTBTFGYVRC-UHFFFAOYSA-N Episclareol Natural products CC1(C)CCCC2(C)C(CCC(O)(C)C=C)C(C)(O)CCC21 XVULBTBTFGYVRC-UHFFFAOYSA-N 0.000 description 4
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 4
- LAEIZWJAQRGPDA-UHFFFAOYSA-N Manoyloxid Natural products CC1(C)CCCC2(C)C3CC=C(C)OC3(C)CCC21 LAEIZWJAQRGPDA-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000001026 1H--1H correlation spectroscopy Methods 0.000 description 2
- OINNEUNVOZHBOX-QIRCYJPOSA-K 2-trans,6-trans,10-trans-geranylgeranyl diphosphate(3-) Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP([O-])(=O)OP([O-])([O-])=O OINNEUNVOZHBOX-QIRCYJPOSA-K 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 240000000716 Durio zibethinus Species 0.000 description 2
- 235000006025 Durio zibethinus Nutrition 0.000 description 2
- OINNEUNVOZHBOX-XBQSVVNOSA-N Geranylgeranyl diphosphate Natural products [P@](=O)(OP(=O)(O)O)(OC/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)O OINNEUNVOZHBOX-XBQSVVNOSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000005100 correlation spectroscopy Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 239000006870 ms-medium Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 238000001821 nucleic acid purification Methods 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 230000028070 sporulation Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- AILDTIZEPVHXBF-UHFFFAOYSA-N Argentine Natural products C1C(C2)C3=CC=CC(=O)N3CC1CN2C(=O)N1CC(C=2N(C(=O)C=CC=2)C2)CC2C1 AILDTIZEPVHXBF-UHFFFAOYSA-N 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 235000003717 Boswellia sacra Nutrition 0.000 description 1
- 240000007551 Boswellia serrata Species 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 240000007311 Commiphora myrrha Species 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- VWFJDQUYCIWHTN-UHFFFAOYSA-N Farnesyl pyrophosphate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-UHFFFAOYSA-N 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 101150053185 P450 gene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000308495 Potentilla anserina Species 0.000 description 1
- 235000016594 Potentilla anserina Nutrition 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- YPZUZOLGGMJZJO-UHFFFAOYSA-N ambrofix Natural products C1CC2C(C)(C)CCCC2(C)C2C1(C)OCC2 YPZUZOLGGMJZJO-UHFFFAOYSA-N 0.000 description 1
- YPZUZOLGGMJZJO-LQKXBSAESA-N ambroxan Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C)[C@@H]1[C@]2(C)OCC1 YPZUZOLGGMJZJO-LQKXBSAESA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229930101531 artemisinin Natural products 0.000 description 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 1
- 229960004191 artemisinin Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001550 polyprenyl Polymers 0.000 description 1
- 125000001185 polyprenyl group Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 108010087432 terpene synthase Proteins 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
- C07C13/28—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
- C07C13/32—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings
- C07C13/62—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with more than three condensed rings
- C07C13/66—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with more than three condensed rings the condensed ring system contains only four rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/613—Unsaturated compounds containing a keto groups being part of a ring polycyclic
- C07C49/617—Unsaturated compounds containing a keto groups being part of a ring polycyclic a keto group being part of a condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
- C11B9/0042—Essential oils; Perfumes compounds containing condensed hydrocarbon rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
- C12N9/0038—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6) with a heme protein as acceptor (1.6.2)
- C12N9/0042—NADPH-cytochrome P450 reductase (1.6.2.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P15/00—Preparation of compounds containing at least three condensed carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
- C12Y106/02—Oxidoreductases acting on NADH or NADPH (1.6) with a heme protein as acceptor (1.6.2)
- C12Y106/02004—NADPH-hemoprotein reductase (1.6.2.4), i.e. NADP-cytochrome P450-reductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01029—Geranylgeranyl diphosphate synthase (2.5.1.29)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一类四环二萜类化合物,包含化学分子式为C20H32的委内瑞拉烯A和化学分子式为C20H30O的委内瑞拉烯B;该化合物通过委内瑞拉烯A与B的生物合成基因簇的自体沉默基因簇激活和异源表达该基因簇的方式,实现了委内瑞拉烯A和B生物合成基因簇中的基因在链霉菌及大肠杆菌中的表达,整个操作过程简单,工艺成熟,成本低廉,环境友好。本发明获得的产物委内瑞拉烯A和委内瑞拉烯B有望应用到食品、香料、医药化工等领域。
Description
技术领域
本发明属于天然产物化学,生物化学与分子生物学及基因工程领域,具体的讲,涉及一类四环二萜类化合物及其制备方法与应用。
背景技术
迄今为止,超过80,000种萜类化合物从人,动物,植物以及微生物中被发现。萜类化合物由多个异戊二烯结构单元组成,代表最大的一类天然产物[1,2]。一般而言,萜类化合物的母核结构(萜烯)的生物合成由萜类合酶催化有限碳链长度的聚异戊烯基焦磷酸(C5n,n=2,3,4等)的环化得到含多环及诸多手性中心的复杂碳氢骨架[3,4]。如,单萜由香叶基焦磷酸(C10)环化得到,倍半萜由法尼基焦磷酸环化(C15)得到,二萜由香叶基香叶基焦磷酸(C20)环化得到等。进一步,经过细胞色素P450酶,FAD依赖的氧化酶,甲基、酰基及糖基转移酶等后修饰酶的催化作用,形成结构骨架及理化性质更为复杂多样的化合物[2]。萜类化合物生理活性丰富多样,如抗肿瘤、抗疟疾、抗菌、抗病毒、抗炎、免疫抑制等,在医疗保健、食品、化妆品、农药、兽药、化工等领域具有广泛的应用价值和前景,与人们的生活生产密不可分[5,6]。典型的萜类化合物代表如,“诺奖分子”抗疟疾药物青蒿素[7];具有强抗肿瘤活性的临床候选药物的紫杉醇[8];人类及哺乳动物不可或缺,广泛参与到体内生长发育及代谢调节的类固醇激素[9];广泛存在传统中药中的活性甾体皂苷类化合物[10]。并且,植物来源的天然色素、香味剂多为萜类化合物,因此其在食品,香精香料工业具有广泛应用[11]。例如,常用的天然色素β-胡萝卜素、番茄红素、虾青素等;食品增味剂薄荷醇、甜菊糖苷等;香精香料定香剂降龙涎醚等。
然而,由于资源及技术限制,尤其是植物(萜类化合物的主要来源)存在生长周期长、萜类化合物产量低、获取成本高昂的缺点,人们直接从自然界中获取新颖骨架的萜类化合物来服务生产生活越来越困难。同时,传统的化学合成的方式获取新的萜类化合物存在反应步骤多、催化选择性差、条件不够温和以及污染环境等缺点,更关键的是其获得全新结构骨架的能力有限。近些年来,随着基因组测序技术及生物信息学的快速发展,人们发现微生物也具备可观的萜类化合物生产潜力。因此,通过针对单个微生物的全基因组分析,采用生物化学、分子生物学与天然产物化学相结合的策略,成为了挖掘新颖的萜类化合物以供基础和应用科学研究的重要手段[12]。
委内瑞拉链霉菌(Streptomyces venezuelae ATCC 15439)作为天然产物生物合成研究领域的模式菌株,其高质量全基因组数据已发布(GenBank:CP013129),且其次级代谢产物丰富、遗传操作体系完备。然而,检索发现目前国内外尚无任何关于通过自体的沉默基因激活的方法表达委内瑞拉链霉菌(Streptomyces venezuelae ATCC 15439)中委内瑞拉烯的生物合成基因簇(GenBank:MN508361)中的基因来生产萜类化合物尤其是委内瑞拉烯A或委内瑞拉烯B,或者通过大肠杆菌中异源表达的方法表达委内瑞拉链霉菌(Streptomyces venezuelae ATCC 15439)中委内瑞拉烯的生物合成基因簇中的基因来生产萜类化合物尤其是委内瑞拉烯A或委内瑞拉烯B,及其分离纯化的报道。
参考文献
[1]MURAI K,LAUTERBACH L,TERAMOTOK,et al.An unusual skeletalrearrangement in the biosynthesis of the sesquiterpene trichobrasilenol fromTrichoderma[J].Angew Chem,2019,131(42):15188-92.
[2]DICKSCHAT J S.Bacterial terpene cyclases[J].Nat Prod Rep,2016,33(1):87-110.
[3]CHRISTIANSON D W.Structural and chemical biology of terpenoidcyclases[J].Chem Rev,2017,117(17):11570-648.
[4]CHRISTIANSON D W.Structural biology and chemistry of the terpenoidcyclases[J].Chem Rev,2006,106(8):3412-42.
[5]HUANG M,LU J-J,HUANG M-Q,et al.Terpenoids:natural products forcancer therapy[J].Expert Opin Inv Drug,2012,21(12):1801-18.
[6]MORIKAWA T,MATSUDA H,YOSHIKAWA M.A review of anti-inflammatoryterpenoids from the incense gum resins frankincense and myrrh[J].J Oleo Sci,2017,ess16149.
[7]KLAYMAN D L.Qinghaosu(artemisinin):an antimalarial drug from China[J].Science,1985,228(4703):1049-55.
[8]ROWINSKY E K,DONEHOWER R C.Paclitaxel(taxol)[J].New Engl J Med,1995,332(15):1004-14.
[9]GOWER D.Modifiers of steroid-hormone metabolism:a review of theirchemistry,biochemistry and clinical applications[J].J Steroid Biochem,1974,5(5):501-23.
[10]MAHATO S B,SARKAR S K,PODDAR G.Triterpenoid saponins[J].Phytochemistry,1988,27(10):3037-67.
[11]BOHLMANN J,KEELING C I.Terpenoid biomaterials[J].The PlantJournal,2008,54(4):656-69.
[12]YAMADA Y,KUZUYAMA T,KOMATSU M,et al.Terpene synthases are widelydistributed in bacteria[J].Proc Natl Acad Sci,2015,112(3):857-62.
发明内容
针对现有技术的不足,本发明要解决的问题是提供一类四环二萜类化合物及其制备方法与应用。
本发明所述的一类四环二萜类化合物,包含了委内瑞拉烯A(venezuelaene A)和委内瑞拉烯B(venezuelaene B),具体是:
一种四环二萜类化合物,其特征在于:所述化合物为含5-5-6-7四环二萜骨架的化合物,其化学分子式为C20H32,结构式如式(1)所示,命名为:委内瑞拉烯A(venezuelaeneA);
一种四环二萜类化合物,其特征在于:所述化合物为含5-5-6-7四环二萜骨架的化合物,其化学分子式为C20H30O,结构式如式(2)所示,命名为:委内瑞拉烯B(venezuelaeneB);
上述四环二萜类化合物的制备方法,其特征在于:通过自体沉默基因激活的方法表达委内瑞拉链霉菌(Streptomyces venezuelae ATCC 15439)中委内瑞拉烯的生物合成基因簇中的基因来获得委内瑞拉烯A或委内瑞拉烯B。
上述四环二萜类化合物的制备方法,其特征在于:通过大肠杆菌中异源表达的方法表达委内瑞拉链霉菌(Streptomyces venezuelae ATCC 15439)中委内瑞拉烯的生物合成基因簇中的基因来获得委内瑞拉烯A或委内瑞拉烯B。
上述方法中所述的委内瑞拉烯的生物合成基因簇,其特征在于:该基因簇含有4个基因,分别为编码二萜合酶VenA的基因venA或其功能等同体,编码细胞色素P450酶VenB和VenC的2个基因venB和venC或其功能等同体,编码香叶基香叶基焦磷酸合酶VenD的基因venD或其功能等同体;其中,所述venA的核苷酸序列如SEQ ID NO:1所示,venB的核苷酸序列如SEQ ID NO:2所示,venC的核苷酸序列如SEQ ID NO:3所示,venD的核苷酸序列如SEQID NO:4所示;或者所述基因核苷酸序列是分别与编码蛋白VenA,VenB,VenC和VenD的氨基酸序列一致性高于80%所对应的DNA编码序列。
具体的,本发明所述四环二萜类化合物委内瑞拉烯A的制备方法,步骤是:
(1)以S.venezuelae ATCC 15439的基因组(GenBank:CP013129)为模板,分别以引物VenA-F/VenA-R,VenD-F/VenD-R和pDR4VenC-F/pDR4VenC-R对二萜合酶的基因venA,香叶基香叶基焦磷酸合酶基因venD和细胞色素P450酶基因venC进行PCR扩增,得到基因venA,venD和venC的PCR产物;然后以大肠杆菌表达载体pET28b或其功能等同体为载体构建venA和venD的共表达载体pET28b-venAD;其中,所述引物核苷酸序列分别是:
VenA-F:CCTGGTGCCGCGCGGCAGCCATATGCAGCAACGCCTCCGCCCG
VenA-R:GTCCACCAGTCATGCTAGCCATATGTCAAACCAGCGGTCGGGTGGG
VenD-F:CCTGGTGCCGCGCGGCAGCCATATGACCCAGGCGACACTGTC
VenD-R:GTCCACCAGTCATGCTAGCCATATGTCATCCGTCGCGGTGGCTCA
pDR4VenC-F:CGTGCAGGACTGGGGGAGTTACTAGTATGACCTGGGCCGCTGCGGGpDR4VenC-R:ATGATTACGAATTCGAGCTCGGTACCTCATGACGCCACCGCCCGGG
(2)将共表达载体pET28b-venAD转化到高产二甲基丙烯基焦磷酸和异戊烯焦磷酸的大肠杆菌工程菌Eco-P(Escherichia coli BL21(DE3)/pACYC-mavEmavS&pTrc-low)化学感受态中,得到能产生委内瑞拉烯A(venezuelaene A)的大肠杆菌工程菌Eco-P/pET28b-venAD;
(3)将大肠杆菌工程菌Eco-P/pET28b-venAD种子液按照体积量1~2:100的比例转接到含卡那霉素、氯霉素和氨苄霉素的TB培养基中于37±2℃,220±20rpm培养,当OD600到达1.0-1.5时,加入终浓度为0.1-1.0mM的异丙基-β-D-硫代半乳糖苷,于18±2℃,220±20rpm的条件下诱导蛋白表达并生物合成委内瑞拉烯A。
具体的,本发明所述四环二萜类化合物委内瑞拉烯B的制备方法,步骤是:
(1)以S.venezuelae ATCC 15439基因组(GenBank:CP013129)为模板,分别以引物VenA-F/VenA-R,VenD-F/VenD-R和pDR4VenC-F/pDR4VenC-R对二萜合酶的基因venA,香叶基香叶基焦磷酸合酶基因venD和细胞色素P450酶基因venC进行PCR扩增,得到基因venA,venD和venC的PCR产物;然后以链霉菌整合型载体pDR4-kasOp*或其功能等同体为载体,将venC整合到SpeI和KpnI双酶切线性化的pDR4-kasOp*得到表达载体pDR4-kasOp*-venC;其中,所述引物核苷酸序列分别是:
VenA-F:CCTGGTGCCGCGCGGCAGCCATATGCAGCAACGCCTCCGCCCG
VenA-R:GTCCACCAGTCATGCTAGCCATATGTCAAACCAGCGGTCGGGTGGG
VenD-F:CCTGGTGCCGCGCGGCAGCCATATGACCCAGGCGACACTGTC
VenD-R:GTCCACCAGTCATGCTAGCCATATGTCATCCGTCGCGGTGGCTCA
pDR4VenC-F:CGTGCAGGACTGGGGGAGTTACTAGTATGACCTGGGCCGCTGCGGG
pDR4VenC-R:ATGATTACGAATTCGAGCTCGGTACCTCATGACGCCACCGCCCGGG
(2)将表达载体pDR4-kasOp*-venC转化到商品化的大肠杆菌ET12567/pUZ8002中,得到大肠杆菌工程菌Et12567/pUZ8002&pDR4-kasOp*-venC;将S.venezuelaene ATCC15439野生型的孢子悬液与大肠杆菌工程菌Et12567/pUZ8002&pDR4-kasOp*-venC混合,分别均匀涂布于含MgCl2和CaCl2的MS平板上,于30±2℃培养16±1h后,每个MS平板用溶有潮霉素和萘啶酮酸的无菌水覆盖,待干后,重新放置于30±2℃条件下培养,待3-5天菌落长出后,挑取单菌落到含萘啶酮酸和潮霉素的MS培养基上,3±1天产孢后,接种到2×YT培养液中,28±1℃,220±20rpm培养2天后提取基因组,经PCR验证基因型正确的即为重组菌株S.venezuelae ATCC 15439/pDR4-kasOp*-venC;
(3)按照体积量1~2:10的比例将重组菌株S.venezuelae ATCC 15439/pDR4-kasOp*-venC种子液转接到SCM培养基中,30±2℃,220±20rpm培养12h后,以终浓度5mg/L饲喂委内瑞拉烯A,继续培养7~8天,实现委内瑞拉烯A到委内瑞拉烯B的生物转化,得到经GC检测转化率达95%的委内瑞拉烯B。
上述四环二萜类化合物的制备方法中:可以将含委内瑞拉烯A或委内瑞拉烯B的发酵液加入等体积的乙酸乙酯萃取,再蒸干得到的浸膏,浸膏用正己烷萃取去除极性大的组分,萃取液再蒸干并溶于乙腈用于反相C18色谱柱半制备获得纯化的委内瑞拉烯A或委内瑞拉烯B;其中,色谱柱为Waters XBridgeTM C-18column,规格10×250mm、5μm,洗脱程序为:100%甲醇洗脱30min,流速为1.5~2.5mL/min。
本发明所述四环二萜类化合物委内瑞拉烯A(venezuelaene A)在制备香料中的应用。
本发明所述四环二萜类化合物委内瑞拉烯B(venezuelaene B)在制备香料中的应用。
本发明提供了一类四环二萜类化合物及其制备方法与应用。研发过程中发明人通过基因组挖掘的策略从委内瑞拉链霉菌(Streptomyces venezuelae ATCC 15439)中发现了新颖的委内瑞拉烯A与B的生物合成基因簇。通过沉默基因激活和异源表达的方式,实现了委内瑞拉烯A和B生物合成基因簇中的基因在链霉菌及大肠杆菌中的表达。最终,分离纯化获得了两个具有全新骨架的5-5-6-7四环二萜类化合物,即带有香味的委内瑞拉烯A和委内瑞拉烯B。其中的创新点体现在利用基因工程的方法,构建产生新化合物委内瑞拉烯A的自给自足工程菌。随后,利用生物转化的方法,应用表达P450基因venC的工程菌S.venezuelae ATCC 15439/pDR4-kasOp*-venC一步完成委内瑞拉烯A到新化合物委内瑞拉烯B的转化。整个操作过程简单,工艺成熟,成本低廉,整个过程不含有害杂质,无毒,对环境非常友好。获得的产物委内瑞拉烯A和委内瑞拉烯B有望应用到食品、香料、医药化工等领域。
附图说明
图1为本发明实施例提供的委内瑞拉烯A的三维结构椭球图。
图2为本发明实施例提供的委内瑞拉烯A(venezuelaene A)和委内瑞拉烯B(venezuelaene B)的化学结构图。
图3为本发明实施例提供的委内瑞拉烯A的紫外可见光谱图。
图4为本发明实施例提供的委内瑞拉烯A的气相质谱图。
图5为本发明实施例提供的委内瑞拉烯A的1H-1H COSY,HMBC和NOESY的关键相关信号。
图6为本发明实施例提供的委内瑞拉烯A在CD3Cl中的1HNMR图。
图7为本发明实施例提供的委内瑞拉烯A在CD3Cl中的13CNMR图。
图8为本发明实施例提供的委内瑞拉烯A在CD3Cl中的13C-DEPT 135°图。
图9为本发明实施例提供的委内瑞拉烯A在CD3Cl中的HSQC图。
图10为本发明实施例提供的委内瑞拉烯A在CD3Cl中的1H-1H COSY图。
图11为本发明实施例提供的委内瑞拉烯A在CD3Cl中的HMBC图。
图12为本发明实施例提供的委内瑞拉烯A在CD3Cl中的NOSEY图。
图13为本发明实施例提供的GC检测委内瑞拉烯A(1)到委内瑞拉烯B的生物转化图(2)。
其中:(i)为S.venezuelae ATCC 15439饲喂5mg/L委内瑞拉烯A;(ii)为工程菌S.venezuelae ATCC 15439/pDR4-kasOp*-venC饲喂5mg/L委内瑞拉烯A。
图14为本发明实施例提供的委内瑞拉烯B的紫外可见光谱图。
图15为本发明实施例提供的委内瑞拉烯B的气相质谱图。
图16为本发明实施例提供的委内瑞拉烯B的高分辨质谱图。
图17为本发明实施例提供的委内瑞拉烯B的1H-1H COSY,HMBC和NOESY的关键相关信号。
图18为本发明实施例提供的委内瑞拉烯B在CD3Cl中的1HNMR图。
图19为本发明实施例提供的委内瑞拉烯B在CD3Cl中的13C-DEPTQ图。
图20为本发明实施例提供的委内瑞拉烯B在CD3Cl中的HSQC图。
图21为本发明实施例提供的委内瑞拉烯B在CD3Cl中的1H-1H COSY图。
图22为本发明实施例提供的委内瑞拉烯B在CD3Cl中的HMBC图。
图23为本发明实施例提供的委内瑞拉烯B在CD3Cl中的NOSEY图。
具体实施方式
下面结合具体实施例对本发明内容进行详细说明。如下所述例子仅是本发明的较佳实施方式而已,并非对本发明作任何形式上的限制,凡是依据本发明的技术实质对实施方式所做的任何简单修改,等同变化与修饰,均属于本发明技术方案的范围内。
本发明实施例中所采用的PCR扩增,质粒提取、转化等基础分子生物学实验技术,如无特殊说明,通常按照常规方法操作,具体可参见《分子克隆实验指南》(第三版)(Sambrook J,Russell DW,Janssen K,Argentine J.黄培堂等译,2002,北京:科学出版社),或按照相关产商提供的说明书执行。
本发明实施例所用菌株S.venezuelaene ATCC 15439购自美国菌种保藏中心;Escherichia coli BL21(DE3)感受态细胞购自北京擎科。大肠杆菌工程菌Eco-P(Escherichia coli BL21(DE3)/pACYC-mavEmavS&pTrc-low)的构建方法见Microb CellFact 15,74(2016);大肠杆菌Et12567/pUZ8002购自优宝生物公司。
本发明实施例所用一步克隆试剂盒购自南京诺唯赞公司;琼脂糖凝胶DNA回收试剂盒购自Omega公司;链霉菌整合型载体pDR4-kasOp*购自Addgene;大肠杆菌表达载体pET28b购自Invitrogen;高保真DNA聚合酶购自Takara;限制性内切酶购自赛默飞;PCR引物合成和DNA测序由北京擎科完成。
本发明实施例所涉及的S.venezuelae ATCC 15439的生孢培养基为MS培养基,配方是:豆粉20g/L,甘露醇20g/L,琼脂粉20g/L;种子培养基为2×YT培养基,配方是:胰蛋白胨16g/L,酵母提取物10g/L,NaCl 5g/L;发酵培养基为SCM培养基,配方是:可溶性淀粉15g/L,大豆蛋白胨20g/L,CaCl2 0.1g/L,酵母提取物1.5g/L,3-吗啉丙磺酸10.5g/L,pH 7.2。
本发明实施例所涉及的肠杆菌的种子培养基为LB培养基,配方是:胰蛋白胨10g/L,酵母提取物5g/L,NaCl 10g/L;发酵培养基为TB培养基,配方是:胰蛋白胨12g/L,酵母提取物24g/L,甘油40g/L,K2HPO4 9.4g/L,KH2PO4 2.2g/L。
实施例1基因表达载体构建
以S.venezuelae ATCC 15439的基因组为模板,分别以引物VenA-F/VenA-R,VenD-F/VenD-R和pDR4VenC-F/pDR4VenC-R(表1)对二萜合酶的基因venA,香叶基香叶基焦磷酸合酶基因venD和细胞色素P450酶基因venC进行PCR扩增,反应体系如下:5×PrimeSTAR GXLBuffer 10μL,200μM dNTPs,4μL DMSO,上下游引物各0.3μM,DNA模板适量(10-100ng),高保真聚合酶(PrimeSTAR GXL DNA聚合酶)2.5U,ddH2O补足至50μL;反应条件为:98℃预变性5min,98℃变性30s,60℃退火15s,68℃延伸(1kb/min,根据目的片段长度设定时间),反应35个循环,最后68℃延伸10min。基因venA,venD和venC的PCR产物经核酸纯化试剂盒纯化后,利用一步克隆试剂盒将venA和venD分别整合到NdeI酶切消化后的线性pET28b分别得到大肠杆菌中的蛋白表达质粒pET28b-venA和pET28b-venD;进一步,为了构建venA和venD的共表达载体,以pET28b-venA作为模板,利用引物28bVenA-F/28bVenA-R进行PCR得到线性化质粒。随后,以pET28b-venD作为模板,利用引物T7VenD-F/T7VenD-R进行PCR得到包含T7启动子和终止子序列和venD的DNA片段,并克隆到上述准备好的线性化pET28b-venA上得到包含2个T7启动子的venA和venD的共表达载体pET28b-venAD。
同样,以如上方法在基因venA,venD和venC的PCR产物经核酸纯化试剂盒纯化后,利用一步克隆试剂盒将venC整合到SpeI和KpnI双酶切线性化的pDR4-kasOp*得到表达载体pDR4-kasOp*-venC。
表1:实例中用到的引物序列
实施例2构建重组大肠杆菌,发酵生产委内瑞拉烯A
将pET28b-venAD转化到提前制备好的高产二甲基丙烯基焦磷酸和异戊烯焦磷酸的大肠杆菌工程菌Eco-P(Escherichia coli BL21(DE3)/pACYC-mavEmavS&pTrc-low)化学感受态中,得到自给自足生产委内瑞拉烯A(venezuelaene A)的大肠杆菌工程菌Eco-P/pET28b-venAD。
从LB固体平板(胰蛋白胨10g/L,酵母提取物5g/L,NaCl 10g/L,15g/L琼脂粉)上挑取Eco-P/pET28b-venAD接种到20mL含有50μg/mL卡那霉素,25μg/mL氯霉素和100μg/mL氨苄霉素的LB液体培养基(胰蛋白胨10g/L,酵母提取物5g/L,NaCl 10g/L)中,于37℃,220rpm过夜培养。然后,种子液按照体积量1:100的比例转接到2L含50μg/mL卡那霉素,25μg/mL氯霉素和100μg/mL氨苄霉素的TB培养基(胰蛋白胨12g/L,酵母提取物24g/L,甘油40g/L,K2HPO49.4g/L,KH2PO4 2.2g/L)中于37℃,220rpm培养。当OD600到达1.0-1.5,加入终浓度为0.2mM异丙基-β-D-硫代半乳糖苷,于18℃,220rpm的条件下诱导蛋白表达并生物合成委内瑞拉烯A。
委内瑞拉烯A的分离纯化及结构鉴定
待重组大肠杆菌Eco-P/pET28b-venAD发酵3天后,加入等体积的乙酸乙酯萃取三次,利用旋转蒸发仪蒸干萃取液得到浸膏。然后,浸膏再用50mL正己烷萃取四次从而去除极性大的组分。最后,正己烷萃取液蒸干,并溶于乙腈用于反相C18色谱柱半制备获得委内瑞拉烯A。具体的色谱柱为Waters XBridgeTM C-18 column(10×250mm,5μm),洗脱程序为:100%甲醇洗脱30min,流速为2.5mL/min。最终得到的委内瑞拉烯A经氮气吹干后为无色透明油状,比旋度=-20°(c 0.165,CH2Cl2),并有持久保持、令人愉悦的香味。进一步,为了完成委内瑞拉烯A的结构鉴定和解析,取10mg委内瑞拉烯A溶解于0.5mL色谱纯乙腈中,于4℃自然挥发,约一周后形成了针状晶体供X射线单晶衍射分析得到其三维结构(附图1)。基于新化合物委内瑞拉烯A(分子式:C20H32)的化学结构(附图2),以及相应的紫外可见光谱(附图3),气相质谱(附图4),核磁共振谱图(附图5-12)分析,将其化学位移归属于表2。
表2:实施例中委内瑞拉烯A的
1H NMR(600MHz,CDCl3)和13C NMR(151MHz,CDCl3)化学位移归属
实施例3构建重组菌株S.venezuelae ATCC 15439/pDR4-kasOp*-venC,饲喂委内瑞拉烯A生物转化得到委内瑞拉烯B
从MS培养基(豆粉20g/L,甘露醇20g/L,琼脂粉20g/L)上收集培养5-7天的新鲜S.venezuelaene ATCC 15439野生型的孢子,重悬于5mL 2×YT培养液(胰蛋白胨16g/L,酵母提取物10g/L,NaCl 5g/L)。用等体积2×YT溶液洗涤3-5次后,6000rpm离心2min后,将孢子悬液浓缩至500μL。于50℃热激10min后,孢子悬液冷却至常温。分别取100μLS.venezuelaene ATCC 15439野生型的孢子悬液与100μL提前准备好的大肠杆菌Et12567/pUZ8002&pDR4-kasOp*-venC混合,分别均匀涂布于含50mM MgCl2和50mM CaCl2的MS平板上。于30℃培养16h后,每个MS平板用溶有25mg潮霉素和0.5mg萘啶酮酸的1mL无菌水覆盖,待干后,重新放置于30℃条件下培养。待3-5天菌落长出后,挑取单菌落到含25μg/mL萘啶酮酸和50μg/mL潮霉素的MS培养基。约3天产孢后,接种到4mL2×YT培养液中,28℃,220rpm培养2天后提取基因组供PCR验证基因型,得到正确的即为重组菌株S.venezuelae ATCC 15439/pDR4-kasOp*-venC。
从MS平板上挑取工程菌S.venezuelae ATCC 15439/pDR4-kasOp*-venC的单克隆接种到500mL 2×YT培养液中。30℃,220rpm培养2天后,按照体积量1:10的比例转接到5LSCM培养基(可溶性淀粉15g/L,大豆蛋白胨20g/L,CaCl2 0.1g/L,酵母提取物1.5g/L,3-吗啉丙磺酸10.5g/L,pH 7.2)中。30℃,220rpm培养12h后,以终浓度5mg/L饲喂委内瑞拉烯A,继续培养7天,从而实现委内瑞拉烯A到委内瑞拉烯B的生物转化,经GC检测转化率可达95%(附图13)。相比而言,对照组的野生株S.venezuelae ATCC 15439中委内瑞拉烯的生物合成基因簇在常规培养条件下是沉默的,因此无法实现饲喂的委内瑞拉烯A到委内瑞拉烯B的生物转化(附图13)。
委内瑞拉烯B的分离纯化及结构鉴定
将上述5L S.venezuelae ATCC 15439/pDR4-kasOp*-venC的发酵液加入等体积的乙酸乙酯萃取三次后得到的萃取液利用真空旋转蒸发仪蒸干。得到的浸膏再用50mL正己烷萃取四次去除极性大的组分后,萃取液蒸干溶于乙腈用于反相C18色谱柱半制备获得委内瑞拉烯B。具体的色谱柱为Waters XBridgeTM C-18 column(10×250mm,5μm),洗脱程序为:100%甲醇洗脱30min,流速为1.5mL/min。最终得到委内瑞拉烯B经氮气吹干后为白色粉末,比旋度=-113.1(c 0.065,CH2Cl2)并有类似委内瑞拉烯A的令人愉悦的香味。结合紫外可见光谱(附图14),气相质谱(m/z=286,附图15)及高分辨质谱([M+H]+:calc.287.2369;obs.287.2357,附图16),核磁共振谱(附图17-23)分析,确定了新化合物委内瑞拉烯B的化学结构(附图2),并将其化学位移归属于表3。
表3:实施例中委内瑞拉烯B的
1H NMR(600MHz,CDCl3)和13C NMR(151MHz,CDCl3)化学位移归属
实施例4四环二萜类化合物委内瑞拉烯A(venezuelaene A)在制备香料中的应用
常温条件下,四环二萜类化合物委内瑞拉烯A(venezuelaene A)以浓度1mg/mL溶解于挥发性溶剂中,例如甲醇、乙醇、丙酮、乙酸乙酯等,会展现出持久的淡淡的木香,类似于香紫苏醇。并且,当真空条件下通过旋转蒸发获得委内瑞拉烯A油状液体时,其会呈现出类似榴莲的浓郁气味。基于委内瑞拉烯A的芬芳特性,且通过体外测试无细胞毒性,预示其可以广泛应用到香精香料制备工业上,有望替代香紫苏醇等二萜香料。
实施例5四环二萜类化合物委内瑞拉烯B(venezuelaene B)在制备香料中的应用
常温条件下,四环二萜类化合物委内瑞拉烯B(venezuelaene B)以浓度1mg/mL溶解于挥发性溶剂中,例如甲醇、乙醇、丙酮、乙酸乙酯等,会展现出持久的淡淡的木香,类似于香紫苏醇。并且,在真空条件下通过旋转蒸发获得委内瑞拉烯B的油状液体时,其会呈现出类似榴莲的浓郁气味。基于委内瑞拉烯B的芬芳特性,且通过体外测试无细胞毒性,预示其可以广泛应用到香精香料制备工业上,有望替代香紫苏醇等二萜香料。
序列表
<110> 山东大学,中国科学院青岛生物能源与过程研究所
<120> 一类四环二萜类化合物及其制备方法与应用
<141> 2019-10-30
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1161
<212> DNA
<213> 委内瑞拉链霉菌(Streptomyces venezuelae)ATCC 15439
<221> 基因venA的核苷酸序列
<400> 1
atgcagcaac gcctccgccc gcttccgccg atctggagaa ccaaggtgat caccgacgtc 60
gacctcaccc gtcgcctcct gcccggtgac gggccgggag agttcttcct gccgccgctg 120
ccgcggctgc tgcccgcggg ctaccacccc gacgccgccc gcatcgagat cgcctccaac 180
ggctgggtgc ggcggatgct ggcggactgc ttcgactccg aggagtcgct gctgttcttc 240
ctgcgtcagc gtaacgggat ctacgggccg ctgacggtgc cgtacgccga ggcggacagg 300
gcccagaaca tcgccgactg gtaccagttc gtcacggtga tcgacagctt cgtctccgac 360
gaggcggcac tgggcgccga ccacgcggcg gccgccgaga ccttcgccgc cgtcgtcgcc 420
gacctgcgcg agggcggggc cggcggcccc gccgcgagcc tgtacggccg cgccgcccag 480
gacctgtggc ggcgtatcgc ggccgggatg agcgcacggc aggtcgatcg gctcgtcgcg 540
gccctcgagg cgttcctgcg cgggtgcgcg gaggagatcc gcagcaaact cgacaagcag 600
gtaccgcact tcgaggcgtg catgcgggtg cgggtcgaca gcttcgggtg cgagttcctg 660
gaactgctca ccgagtacgc ggccgaggtc gacatgagcc gggccgcgac agagggcctg 720
ttcgacgagg tccaccacca cggcatgcgg cagctgatcc tcgtcaacga cctgctctcg 780
tggcgcaagg agtacgccca gcgggacacc atgacgaccg tccgcgtgct gtgcgaggtc 840
gaagggcttg agctgcagga cgccgtcgac cggctgtgcg ccctcgtgga gcaccacgaa 900
cgcgcctaca tcacggcacg cgacgcggtg ctggccggcc cccacgggca ccgcgaggac 960
gtccgcgcct atctgtcggg gctcgaccat ctgatcggcg gaagccagga gttcgagtat 1020
ctgacgccgc gctacttcgg cgacggctcg gtgtgggacg gctcgacctc cggctggatc 1080
agtctcaccg cgtcggtggc ccgcttccgt gacgcacccg ctcccgcgcc gagcgcccga 1140
cccacccgac cgctggtttg a 1161
<210> 2
<211> 1437
<212> DNA
<213> 委内瑞拉链霉菌(Streptomyces venezuelae)ATCC 15439
<221> 基因venB的核苷酸序列
<400> 2
ttgaggagcg ccgtgaccac cgtctcgcca ccgccccgca cgatgtccta cgcgctcgcg 60
cccggggccc tgcccctgct cggccacgcc gtgccgctgg cccgccgacc gctggagttc 120
ctgaccgggt tgccccggca cggggacctg gtggaggtcc ggctggggcg ccgccccgcc 180
ctcatggtct gccaccccga gttgatcaag cgtgtactgc tggagccgcg gaccttcgac 240
aagggcgggc cgctgttcga gaaggccgag caactcgtcg gcagcgggct gttcgcggcg 300
acctgggagc cgcaccgcag gcagcggcgg atgatgcagc cgggcttcca caagtcgcgg 360
atgcccgggt acgtggcggt gatgcggcag gagatcgcgg cgctgctcga cggctgggcc 420
gacggccagg aacgcgacgt acgcgatgag atgcacacgg tgacgctccg catcgcctcg 480
cgcaccatgt tcaccaaccc gatgagcggg cgcgccgcgg ccgaggtgca ggagtgcatg 540
ccgatcatca accgcggcgt ctacaagcgg atggtcgcgc cgaccgcgct gctggagaag 600
ctgcccaccc gggagaaccg cgagttccag ctcgcgcacg agcggatgga gcaggtcgtc 660
gacgagacga tcgagcagta ccgcagtgcg ggcgtcgacc acggcgacct gatgtcgatc 720
ctgatcggcg cggtcgacga gggctccggg cagaacatgt ccgagacgga gatccacaag 780
caggtcatga cgctgctggc cggcggcatg gagacgacgg cgaacgcgat ctgctcggcc 840
ctgcacctga tcaccgagca ccccgaggtc gaacggcggc tgtgcgcgga gctcgacgag 900
gtgctggccg gcaggccgcc ggagttcgag gaccttcccc gcctgccgta tctgtaccgg 960
gtgctgtacg agaccctgcg gatccgtccg ccggtgtggc tgctgacccg gatgaccacg 1020
tgcgacaccg agctgggcgg ccaccgcatc ggccgggaca ccatcgtgct gctcagcccc 1080
tatctgctgc accacaaccc ggacctgttc gcccggcccg agacgttcga cccggaccgg 1140
tggctgccgg agcgcgtcga cgacatcacc gaggccgcca tgcagccctt catcatgggc 1200
aaccgcaagt gcatcggtga caagttcgcg ctgaacgagg cgatgatcgt catcgcgacg 1260
atcctgtcgg gctggtcgct tcggatgatc ccggacgcca agcgggtctc gctgcccgag 1320
gcgacgctcg gccccggccc gatgccgatg gtgctgcacc gccgcgccgc cgcgcatcac 1380
gccccggtgc cctcggcccg accgggcgaa tgcccctacc agggcgggcg ttcatga 1437
<210> 3
<211> 1398
<212> DNA
<213> 委内瑞拉链霉菌(Streptomyces venezuelae)ATCC 15439
<221> 基因venC的核苷酸序列
<400> 3
atgacctggg ccgctgcggg accggccgag gccccgcacg ggctgccggt cgtgggccat 60
gccgtgcagt tgtggcggcg cccgctgccc ttcctgcgtg agctgtccgg gcgcggtgac 120
ctcgtgacgc tgcgcctggg ccgccaccgc gcctatctgg cgtgcggcat cgacgcggtg 180
cgcaccgtgc tgcacgatcc gcggacgttc gacaagggcg gcccgctgtt cgagaaggcc 240
cggctgctgg tgggtgacgg tctggtcagt tcggacttcg ccacgcaccg caggcagcgc 300
ctgctgatgc agcccgcgtt cggcacctcg cggcttcccg gctacaccgg gctgatggcc 360
gagcagatcg acacggcgct ggaccggtgg cagcacggcc ggacactcga cgtgggccgg 420
gagatgcaca cgctggccct cgaggtcgcg gcacggacgt tgttcggtgc ccacctgggc 480
gagcgggccg tcaccgaggt cgtcgcgtgc atgccgctgg tcatgcgggg tgtctaccgg 540
cgcatgctcg tcccggccga ctgggtgcac cgcctgccgc tgcccgccaa ccgccgcttc 600
gaccgggccc gggccacgat gcaccgcgtc atcgccgaca ccgtccgctc ctaccgcgac 660
gccgggaagg accacggcga cgtcctgtcg atcctggtga gctcccgcga cgagcacggt 720
acgtcactga gcgacgccga gatccacgac caggtcatga cgctgctcat cggggcgacc 780
gagcccccgg gctccgcgct gacctgggtg ttccagctgc tgtcggagca tcccgaggcc 840
gagcgcgccc tgcgggccga ggccgacgac gtgctgcgcg gcaggccggc cggcgccctg 900
agcgcggcgg acctggcgcg cctggagcac acgcggcaca tcgtgctcga ggcgctgcgg 960
ctctacccgc cggcgtggct gctcagccgc gtcgccacca aggacaccga ccttatgggc 1020
catccggtgc ccaagggtgc cacggtgctg ttcagcccgt accaactcca ccatgaccag 1080
gacgtgttcc cgcatccgtc gcgcttcgac ccgggccgct ggcgctcccc ctcccccgcc 1140
gcccgcgccg cactgctgcc cttcggggcc ggcaaccgca agtgcatcgg cgacgaagtg 1200
gccctgacgg aactgtctct cgcggtcgcc gccgtggcgt cccggttcag gctgcgggcc 1260
gttcccggta cgacggcacg gcccctcgtc cgtgcttcgc tcggtgccga gcacgtggtg 1320
ctgagagtcg aggcacgtac ccccctcggc gcggccgccg gcggcgcgtc ggtcgggtcc 1380
cgggcggtgg cgtcatga 1398
<210> 4
<211> 1080
<212> DNA
<213> 委内瑞拉链霉菌(Streptomyces venezuelae)ATCC 15439
<221> 基因venD的核苷酸序列
<400> 4
atgacccagg cgacactgtc ggccgttctc gtggacgccc cgctgcgccc gcccgtcgag 60
ggcatgcggc ccaccgcggc gtacggtgtg ctggtcgggc ggctgggagc cgccaccgtg 120
cacgcggacc tgcgggcctg cctggagggc atcgacaccg tcgtccgcgc cgcgccgctg 180
gtcatcccgc cggccatggc cgacgtcttc tcgggtggca aacggctgcg tccgctgctg 240
gtcctggccg gcgcgcacgc cgccggcccg ccgtcggcga gcacgcgcgg ccgcgccgtg 300
agcggtgccc gtgccgtgga actgctgcat ctggcgagtc tcgtccacga cgacatcatg 360
gacgaggcgg tgacccggca cggggtcgcg accatcagcg cacgggccgg caacagccgc 420
gccctgctcg ccggcgacta cctcatcggc cacgcgcaca tcgccgcttc cggcctcggc 480
gccgaggcgg gaactctcct gggccacacc ctcgtgcggc tgtgcgaggg ccaggccgag 540
gaagcctcca cgctcttcga cgccgaccgc ggtgaagagt cgtacttcag ggcgatcggc 600
gggaagaccg gtgccctgat cgacgcggcg tgccgcacgg gcgcgctcgc cgcaggcctt 660
gacgccacca cgacccgggc cctgggacgc ttcggccacc atctcggcgt ggggttccaa 720
ctcctcgacg acatgcttga cctgacggca agtcatgcct ctgcgggcaa gccggtgggg 780
cacgacatcg ccaacggcgt ctacacctat cccacgctct gggcgctgcg ccgcgacccc 840
gggctgcggc gactccttga ggaactcgcc cggtgcgaag ggccccgcac cgggccggcc 900
ggcgaggcgg cccaccgggt ccgtgcctcg ggtgcgctca ccgcgacccg gcgggcgatc 960
gcccgtcggc gtgaacgctg cctgggaatc ctggacgagg cggtcgacgg catcggcccc 1020
gacggcgtcg gcctgctggc cgatctcgcc atcgccgtcc tgagccaccg cgacggatga 1080
Claims (10)
3.权利要求1或2所述四环二萜类化合物的制备方法,其特征在于:通过自体沉默基因激活的方法表达委内瑞拉链霉菌Streptomyces venezuelae ATCC 15439中委内瑞拉烯的生物合成基因簇中的基因来获得委内瑞拉烯A或委内瑞拉烯B。
4.权利要求1或2所述四环二萜类化合物的制备方法,其特征在于:通过大肠杆菌中异源表达的方法表达委内瑞拉链霉菌Streptomyces venezuelae ATCC 15439中委内瑞拉烯的生物合成基因簇中的基因来获得委内瑞拉烯A或委内瑞拉烯B。
5.一种权利要求3或4所述的委内瑞拉烯的生物合成基因簇,其特征在于:所述基因簇含有4个基因,分别为编码二萜合酶VenA的基因venA或其功能等同体,编码细胞色素P450酶VenB和VenC的2个基因venB和venC或其功能等同体,编码香叶基香叶基焦磷酸合酶VenD的基因venD或其功能等同体;其中,所述venA的核苷酸序列如SEQ ID NO:1所示,venB的核苷酸序列如SEQ ID NO:2所示,venC的核苷酸序列如SEQ ID NO:3所示,venD的核苷酸序列如SEQ ID NO:4所示。
6.权利要求1所述四环二萜类化合物的制备方法,步骤是:
(1)以S.venezuelae ATCC 15439的基因组为模板,分别以引物VenA-F/VenA-R,VenD-F/VenD-R和pDR4VenC-F/pDR4VenC-R对二萜合酶的基因venA,香叶基香叶基焦磷酸合酶基因venD和细胞色素P450酶基因venC进行PCR扩增,得到基因venA,venD和venC的PCR产物;然后以大肠杆菌表达载体pET28b或其功能等同体为载体构建venA和venD的共表达载体pET28b-venAD;其中,所述引物核苷酸序列分别是:
VenA-F:CCTGGTGCCGCGCGGCAGCCATATGCAGCAACGCCTCCGCCCG
VenA-R:GTCCACCAGTCATGCTAGCCATATGTCAAACCAGCGGTCGGGTGGG
VenD-F:CCTGGTGCCGCGCGGCAGCCATATGACCCAGGCGACACTGTC
VenD-R:GTCCACCAGTCATGCTAGCCATATGTCATCCGTCGCGGTGGCTCA
pDR4VenC-F:CGTGCAGGACTGGGGGAGTTACTAGTATGACCTGGGCCGCTGCGGG
pDR4VenC-R:ATGATTACGAATTCGAGCTCGGTACCTCATGACGCCACCGCCCGGG
(2)将共表达载体pET28b-venAD转化到高产二甲基丙烯基焦磷酸和异戊烯焦磷酸的大肠杆菌工程菌Eco-P即Escherichia coli BL21-DE3/pACYC-mavEmavS&pTrc-low化学感受态中,得到能产生委内瑞拉烯A(venezuelaene A)的大肠杆菌工程菌Eco-P/pET28b-venAD;
(3)将大肠杆菌工程菌Eco-P/pET28b-venAD种子液按照体积量1~2:100的比例转接到含卡那霉素、氯霉素和氨苄霉素的TB培养基中于37±2℃,220±20rpm培养,当OD600到达1.0-1.5时,加入终浓度为0.1-1.0mM异丙基-β-D-硫代半乳糖苷,于18±2℃,220±20rpm的条件下诱导蛋白表达并生物合成委内瑞拉烯A。
7.权利要求2所述四环二萜类化合物的制备方法,步骤是:
(1)以S.venezuelae ATCC 15439基因组为模板,分别以引物VenA-F/VenA-R,VenD-F/VenD-R和pDR4VenC-F/pDR4VenC-R对二萜合酶的基因venA,香叶基香叶基焦磷酸合酶基因venD和细胞色素P450酶基因venC进行PCR扩增,得到基因venA,venD和venC的PCR产物;然后以链霉菌整合型载体pDR4-kasOp*或其功能等同体为载体,将venC整合到SpeI和KpnI双酶切线性化的pDR4-kasOp*得到表达载体pDR4-kasOp*-venC;其中,所述引物核苷酸序列分别是:
VenA-F:CCTGGTGCCGCGCGGCAGCCATATGCAGCAACGCCTCCGCCCG
VenA-R:GTCCACCAGTCATGCTAGCCATATGTCAAACCAGCGGTCGGGTGGG
VenD-F:CCTGGTGCCGCGCGGCAGCCATATGACCCAGGCGACACTGTC
VenD-R:GTCCACCAGTCATGCTAGCCATATGTCATCCGTCGCGGTGGCTCA
pDR4VenC-F:CGTGCAGGACTGGGGGAGTTACTAGTATGACCTGGGCCGCTGCGGG
pDR4VenC-R:ATGATTACGAATTCGAGCTCGGTACCTCATGACGCCACCGCCCGGG
(2)将表达载体pDR4-kasOp*-venC转化到商品化的大肠杆菌Et12567/pUZ8002中,得到大肠杆菌工程菌Et12567/pUZ8002&pDR4-kasOp*-venC;将S.venezuelaene ATCC 15439野生型的孢子悬液与大肠杆菌工程菌Et12567/pUZ8002&pDR4-kasOp*-venC混合,分别均匀涂布于含MgCl2和CaCl2的MS平板上,于30±2℃培养16±1h后,每个MS平板用溶有潮霉素和萘啶酮酸的无菌水覆盖,待干后,重新放置于30±2℃条件下培养,待3-5天菌落长出后,挑取单菌落到含萘啶酮酸和潮霉素的MS培养基上,3±1天产孢后,接种到2×YT培养液中,28±1℃,220±10rpm培养2天后提取基因组,经PCR验证基因型正确的即为重组菌株S.venezuelae ATCC 15439/pDR4-kasOp*-venC;
(3)按照体积量1~2:10的比例将重组菌株S.venezuelae ATCC 15439/pDR4-kasOp*-venC种子液转接到SCM培养基中,30±2℃,220±20rpm培养12h后,以终浓度5mg/L饲喂委内瑞拉烯A,继续培养7~8天,实现委内瑞拉烯A到委内瑞拉烯B的生物转化,得到经GC检测转化率达95%的委内瑞拉烯B。
8.根据权利要求6或7所述四环二萜类化合物的制备方法,其特征在于:将含委内瑞拉烯A或委内瑞拉烯B的发酵液加入等体积的乙酸乙酯萃取,再蒸干得到的浸膏,浸膏用正己烷萃取去除极性大的组分,萃取液再蒸干并溶于乙腈用于反相C18色谱柱半制备获得纯化的委内瑞拉烯A或委内瑞拉烯B;其中,色谱柱为Waters XBridgeTMC-18 column,规格10×250mm、5μm,洗脱程序为:100%甲醇洗脱30min,流速为1.5~2.5mL/min。
9.权利要求1所述四环二萜类化合物委内瑞拉烯A(venezuelaene A)在制备香料中的应用。
10.权利要求2所述四环二萜类化合物委内瑞拉烯B(venezuelaene B)在制备香料中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911072144.7A CN110885281B (zh) | 2019-11-05 | 2019-11-05 | 一类四环二萜类化合物及其制备方法与应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911072144.7A CN110885281B (zh) | 2019-11-05 | 2019-11-05 | 一类四环二萜类化合物及其制备方法与应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110885281A CN110885281A (zh) | 2020-03-17 |
| CN110885281B true CN110885281B (zh) | 2021-05-11 |
Family
ID=69746908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911072144.7A Active CN110885281B (zh) | 2019-11-05 | 2019-11-05 | 一类四环二萜类化合物及其制备方法与应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110885281B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118108568A (zh) * | 2023-03-02 | 2024-05-31 | 山东大学 | 一种新型二萜类化合物及其制备方法、应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100387609C (zh) * | 2003-12-16 | 2008-05-14 | 中国科学院微生物研究所 | 新角蒽环聚酮类抗生素的制造方法 |
| US8143035B2 (en) * | 2006-09-22 | 2012-03-27 | Rice University | Pantothenate kinase overexpression and pantothenic acid supplementation in actinomycetes |
| KR101189756B1 (ko) * | 2010-10-01 | 2012-10-10 | 이화여자대학교 산학협력단 | 신규한 트리코스타틴 유도체 및 이를 포함하는 항암제 |
-
2019
- 2019-11-05 CN CN201911072144.7A patent/CN110885281B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110885281A (zh) | 2020-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yuan et al. | Biosynthesis of mushroom-derived type II ganoderic acids by engineered yeast | |
| Kannenberg et al. | Hopanoid biosynthesis and function in bacteria | |
| Cui et al. | Ginkgolide B produced endophytic fungus (Fusarium oxysporum) isolated from Ginkgo biloba | |
| Bringmann et al. | Different polyketide folding modes converge to an identical molecular architecture | |
| Deng et al. | Systematic identification of Ocimum sanctum sesquiterpenoid synthases and (−)-eremophilene overproduction in engineered yeast | |
| Huang et al. | Marine bacterial aromatic polyketides from host-dependent heterologous expression and fungal mode of cyclization | |
| Loeschcke et al. | The photosynthetic bacteria Rhodobacter capsulatus and Synechocystis sp. PCC 6803 as new hosts for cyclic plant triterpene biosynthesis | |
| Sawai et al. | Molecular characterization of an oxidosqualene cyclase that yields shionone, a unique tetracyclic triterpene ketone of Aster tataricus | |
| Halder et al. | Enhanced trans-resveratrol production in genetically transformed root cultures of Peanut (Arachis hypogaea L.) | |
| Karunanithi et al. | Functional characterization of the cytochrome P450 monooxygenase CYP71AU87 indicates a role in marrubiin biosynthesis in the medicinal plant Marrubium vulgare | |
| Zhao et al. | Biosynthesis of plant-specific alkaloids tetrahydroprotoberberines in engineered Escherichia coli | |
| CN115197172A (zh) | 二倍半萜化合物、其合成基因簇与合成方法 | |
| O'Connor | Strategies for engineering plant natural products: the iridoid-derived monoterpene indole alkaloids of Catharanthus roseus | |
| Luo et al. | Characterization of a sesquiterpene cyclase from the glandular trichomes of Leucosceptrum canum for sole production of cedrol in Escherichia coli and Nicotiana benthamiana | |
| Madhour et al. | Biosynthesis of the xanthophyll plectaniaxanthin as a stress response in the red yeast Dioszegia (Tremellales, Heterobasidiomycetes, Fungi) | |
| Lu et al. | Heterologous biosynthesis of medicarpin using engineered Saccharomyces cerevisiae | |
| Zhu et al. | Huoshanmycins A‒C, New Polyketide Dimers Produced by Endophytic Streptomyces sp. HS-3-L-1 From Dendrobium huoshanense | |
| Jiang et al. | Schultriene and nigtetraene: two sesterterpenes characterized from pathogenetic fungi via genome mining approach | |
| Tong et al. | Eudesmane-type sesquiterpene diols directly synthesized by a sesquiterpene cyclase in Tripterygium wilfordii | |
| CN110885281B (zh) | 一类四环二萜类化合物及其制备方法与应用 | |
| Liu et al. | Cloning and functional characterization of the polyketide synthases based on genome mining of Preussia isomera XL-1326 | |
| Akhgari et al. | Single cell mutant selection for metabolic engineering of actinomycetes | |
| CN107119001B (zh) | 基因工程化类球红细菌及其制备方法和法尼醇的生产方法 | |
| Gupta et al. | Biotechnology of terpenoid production from microbial cell factories | |
| Ladhari et al. | Unravelling triterpene biosynthesis through functional characterization of an oxidosqualene cyclase (OSC) from Cleome arabica L |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |